← Back to Clinical Trials
Recruiting NCT06438640

NCT06438640 Evaluating a Strategy to Improve Pre-Anesthesia Care Discussions (My Anesthesia Choice-Hip Fracture)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06438640
Status Recruiting
Phase
Sponsor University of Pennsylvania
Condition Hip Fractures
Study Type INTERVENTIONAL
Enrollment 1,881 participants
Start Date 2024-08-15
Primary Completion 2027-06-15

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
My Anesthesia Choice-HF Model

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 1,881 participants in total. It began in 2024-08-15 with a primary completion date of 2027-06-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The objective of this study is to assess the implementation process for and the effectiveness of a quality improvement (QI) strategy to increase shared decision-making around anesthesia options for hip fracture surgery at 6 US hospitals. The QI strategy is to be facilitated by a clinician-administered 1-page bedside conversation aid designed to improve the quality of physician-patient communication, paired with brief clinician training. The evaluation will occur via a stepped wedge, cluster randomized trial to be carried out over a period of 34 months.

Eligibility Criteria

Inclusion: Age 50 and older Planned surgery to treat a hip fracture Exclusion: Contraindication to spinal anesthesia: current anticoagulant therapy or coagulopathy Contraindication to spinal anesthesia: critical aortic stenosis Contraindication to spinal anesthesia: skin infection over the lumbar spine

Contact & Investigator

Central Contact

Mark Neuman, MD

✉ neumanm@pennmedicine.upenn.edu

📞 215-746-7468

Principal Investigator

Mark Neuman, MD

PRINCIPAL INVESTIGATOR

University of Pennsylvania

Frequently Asked Questions

Who can join the NCT06438640 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, studying Hip Fractures. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06438640 currently recruiting?

Yes, NCT06438640 is actively recruiting participants. Contact the research team at neumanm@pennmedicine.upenn.edu for enrollment information.

Where is the NCT06438640 trial being conducted?

This trial is being conducted at Gainesville, United States, Detroit, United States, Lebanon, United States, Winston-Salem, United States and 2 additional locations.

Who is sponsoring the NCT06438640 clinical trial?

NCT06438640 is sponsored by University of Pennsylvania. The principal investigator is Mark Neuman, MD at University of Pennsylvania. The trial plans to enroll 1,881 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology